Six-gene Assay as a new biomarker in the blood of patients with colorectal cancer: establishment and clinical validation

Xin Shou¹, Yong Li², Weilei Hu³, Tingting Ye¹, Guosheng Wang¹, Feng Xu², Meihua Sui³ and Yibing Xu¹

¹ Institute of Translational Medicine, Zhejiang University School of Medicine, Hangzhou, China
² Department of Medical Oncology, Shanghai Gongli Hospital, Second Military Medical University, Shanghai, China
³ Center for Cancer Biology and Innovative Therapeutics, Key Laboratory of Tumor Molecular Diagnosis and Individualized Medicine of Zhejiang Province, Clinical Research Institute, Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical College, China

Keywords biomarker; circulating tumor cells; colorectal cancer; RT-PCR; Six-gene Assay

Colorectal cancer (CRC) is the second most common cancer in men and the third most common cancer in women. Although long-term survival has improved over the past 30 years, at least 50% of patients with CRC will develop metastases after diagnosis. In this study, we examined whether quantifying the mRNA of six CRC-related genes in the blood could improve disease assessment through detection of circulating tumor cells (CTC), and thereby improve progression prediction in relapsed CRC patients. Cell spiking assay and RT-PCR were performed with blood samples from healthy volunteers spiked with six CRC cell lines to generate an algorithm, herein called the Six-gene Assay, based on six genes (CEA, EpCAM, CK19, MUC1, EGFR and C-Met) for CTC detection. The CTCs of 50 relapsed CRC patients were then respectively measured by CEA Gene Assay (single-gene assay control) and Six-gene Assay. Subsequently, receiver operating characteristic analysis of the CTC panel performance in diagnosing CRC was conducted for both assays. Moreover, the 2-year progression-free survival (PFS) of all patients was collected, and the application of CEA Gene Assay and Six-gene Assay in predicting PFS was carefully evaluated with different CTC cutoff values. Encouragingly, we successfully constructed the first multiple gene-based algorithm, named the Six-gene Assay, for CTC detection in CRC patients. Six-gene Assay was more sensitive than CEA Gene Assay; for instance, in 50 CRC patients, the positive rate of Six-gene Assay in CTC detection was 82%, whereas that of CEA Gene Assay was only 70%. Moreover, Six-gene Assay was more sensitive and accurate than CEA Gene Assay in diagnosing CRC as well as predicting the 2-year PFS of CRC patients. Statistical analysis demonstrated that CTC numbers measured by Six-gene Assay were significantly associated with 2-year PFS. This novel Six-gene Assay improves the definition of disease status and correlates with PFS in relapsed CRC, and thus holds promise for future clinical applications.

Abbreviations
CRC, colorectal cancer; CTC, circulating tumor cells; Ct, cycle threshold; GM, geometric mean; PBMC, peripheral blood mononuclear cells; PFS, progression-free survival; RIN, RNA integrity numbers; ROC, receiver operating characteristic; TRC, transcription–reverse transcription concerted reaction.
1. Introduction

Colorectal cancer (CRC) is the second most common cancer in men and the third most common cancer in women (Siegel et al., 2018). The incidence rates are higher in developed countries than in developing ones. Although its long-term survival has been improved over the past 30 years with multi-modality therapy, at least 50% of patients with CRC will develop metastases after diagnosis, leading to a poor prognosis with a 5-year overall survival rate of 12.5% (Siegel et al., 2017; Van Cutsem et al., 2014). Therefore, new therapeutic strategies are needed to improve the outcome of patients with relapsed CRC. However, these likely will be based on studies that include sequencing of CRC cells to identify actionable targets, defining targets in the tumor microenvironment attributed to tumor growth and resistance to therapy, and evaluating disease burden accurately to predict response and prognosis (Grasso et al., 2018; Punt et al., 2017; Sanchez-Lopez et al., 2016; Stadler et al., 2016; Yaeger et al., 2018).

It has been indicated that evaluation of disease burden by quantifying circulating tumor cells (CTC) in blood may contribute to response assessment and prognostication (Haber and Velculescu, 2014; Lalmahomed et al., 2015). For instance, studies have been performed at the time of diagnosis or during initial therapy prior to disease progression using CellSearch® (EpCAM antigen-based) and Transcription-Reverse Transcription Concerted Reaction (TRC, CEA mRNA-based) methods. These methods have provided useful information on CRC patients (Gorges et al., 2016; Sato et al., 2012). However, due to the heterogeneity of CTC, single antigens alone, such as EpCAM or CEA, are not sufficient to capture all the CTC in blood. This could explain why CellSearch® and TRC methods generate much lower yields of CTC than expected. As reported previously, only 30-40% of CRC patients harbor three or more CTC per 7.5 mL of blood using the immunomagnetic CellSearch® detection system (Gorges et al., 2016), and only 60% of CRC patients were shown to be positive in the CTC test with blood samples using the TRC method (Sato et al., 2012). Therefore, a combined analysis of more than one gene could improve the sensitivity of CTC detection by increasing the range of CTC markers, giving an important advantage in view of the well-known phenotypic heterogeneity of CTC.

Dozens of CRC biomarkers have been identified by different technologies, e.g. microarray profiling (Yanagawa et al., 2001), high-throughput gene sequencing (Kim et al., 2011) and mutation detection (Mao et al., 2015). As a result, several multiple gene-based assays have been reported for diagnosis of primary CRC tumors, as well as for the prognostic prediction of CRC (Ning et al., 2015; Okugawa et al., 2015; Shimada et al., 2012). Despite the fact that CTC fall off primary tumors, they carry gene expression signatures different from those of the primary tumors (Chaffer and Weinberg, 2011). This suggests that biomarkers from primary tumors may not satisfy the demand to quantify CTC because of their heterogeneity in gene expression. In this study, after a careful evaluation of the expression level of CRC-related biomarkers in patient tissues and CRC cell lines (de Albuquerque et al., 2012; Cayrefourcq et al., 2015; Cohen et al., 2006; Gasch et al., 2013; Inuma et al., 2011), we selected six genes—CEA, EpCAM, CK19, MUC1, EGFR and C-Met—and evaluated their potential as biomarkers for CTC detection and prognostic prediction of CRC. We successfully constructed the first multiple gene-based algorithm, here denoted the Six-gene Assay, for quantifying the number of CTC in CRC patients based on mRNA level of the above six genes. Moreover, using CEA Gene Assay as a single-gene assay control, we demonstrated that this novel Six-gene Assay is superior in both CTC detection and prediction of progression-free survival (PFS) in CRC patients.

2. Material and methods

2.1. Cell cultures

Human colon cancer cell lines HCA-7, LoVo, SW620, RKO, SW1116 and SW48 were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA) and cultured according to the recommended protocols. In brief, SW48, SW620 and SW1116 cell lines were cultured in flasks containing RPMI-1640 medium, LoVo cell line was cultured in Ham's F-12K medium, HAC-7 cell line was cultured in Dulbecco's modified Eagle's medium, and RKO cell line was cultured in Eagle's minimal essential medium. All culture media were supplemented with 10% FBS (Gibco, Grand Island, NY, USA). These CRC cell lines were selected as they express different levels of six validated genes (CEA, EpCAM, CK19, MUC1, EGFR and C-Met).

2.2. Patients and healthy volunteers

The study was designed in accordance with the Declaration of Helsinki, and was performed following the protocols and informed consent documents approved by the Institutional Review Board of Shanghai Gongli Hospital (Shanghai, China). Fifty relapsed patients with stage III or stage IV CRC at diagnosis were included.
between January 2015 and January 2017 (Table 1). All patients were treated with chemotherapy and none of them underwent radical surgery for the tumors after relapse. Patients were monitored by CT scanning for tumor progression. In addition, 10 healthy volunteers who were clear of polyps under colonoscopy and had no family history of CRC were enrolled as controls. Written consent forms were obtained from all patients and healthy volunteers prior to study enrollment.

2.3. Sample processing and RNA extraction

A peripheral blood sample (5.0 mL) was drawn from each patient or healthy volunteer into PAXgene vials (BD, Biosciences, San Jose, CA, USA). All the samples were maintained at room temperature (20–25 °C) and processed within 72 h after collection. Mononuclear cells from each peripheral blood sample were isolated by density separation with Ficoll-Paque (GE Healthcare, Little Chalfont, Buckinghamshire, UK). RNA was extracted from mononuclear cells using an RNeasy® Plus Micro Kit (Qiagen, Duesseldorf, Germany) according to the manufacturer’s instructions. The extracted RNA was eluted with 20 μL of RNase-free water. For RNA quality control, the ratios of the absorbance (A) at wavelengths of 260 and 280 nm were determined for all samples, which were between 1.90 and 2.10. To further determine the quality of RNA, an RNA integrity test was performed as previously described (Schroeder et al., 2006). The average RNA integrity number (RIN) of the specimens used in this study was 9.1 (range 8.0–10.0).

2.4. Reverse transcription polymerase chain reaction (RT-PCR)

Total RNA extracted from peripheral blood mononuclear cells (PBMC) was reverse transcribed using M-MLV reverse transcriptase (Promega, Madison, WI, USA) according to the manufacturer’s instructions. RT-PCR assays were then performed to assess mRNA expression level of CEA, EpCAM, CK19, MUC1, EGFR and C-Met in 20 μL reaction mixture using SYBR Green PCR Master Mix (Takara, Tokyo, Japan) and the ViiA™ 7 Real-Time PCR System (Applied Biosystems, Foster City, CA, USA). B2M and GAPDH were used as internal control genes. The specific primers of 5’-GCAGCTGTCCATGA-CAACA-3’ and 5’-GGACGGTAATAGGTGTATGA-3’ were used to amplify the human CEA coding region; the specific primers of 5’-TGCTGGAATTGTGTGCTGG-3’ and 5’-AAGA TGCTTCTGCTCCACGC-3’ were used to amplify the human EpCAM coding region; the specific primers of 5’-GGTGAAAGATCCGCACTG-3’ and 5’-CTGCTCTAAACTTGGTCGGA-3’ were used to amplify the human CK19 coding region; the specific primers of 5’-CTCTTCAATATTAAGTTCAAGG-3’ and 5’-GAAAGGAAATGTCACACT-3’ were used to amplify the human MUC1 coding region; the specific primers of 5’-TGTGCCATACCATTGACGG-3’ and 5’-TAGGCCCATTCGTTGACAG-3’ were used to amplify the human EGFR coding region; and the specific primers of 5’-TTGGAAATGAGAGCTGACCT-3’ and 5’-TCGGCGAAATACTTGTGATT-3’ were used to amplify the human C-Met coding region. The specific primers of 5’-TGCTTCTACGAAGGACTG-3’ and 5’-CATCCATCCAAATGCGC-3’ were used to amplify the human B2M coding region, and the specific primers of 5’-GGAGCCAAAAAGGTGTCATCT-3’ and 5’-GAGCCGAATCCACCTCCAACACT-3’ were used to amplify the human GAPDH coding region.

Table 1. Clinicopathologic characteristics of patients with CRC.

| Variable             | Category | No. of patients/age in years |
|----------------------|----------|-----------------------------|
| Sex                  | Male     | 28                          |
|                      | Female   | 22                          |
| Age at diagnosis     | Median in years | 67 (45–78)     |
| Stage at diagnosis   | Stage III | 38                          |
|                      | Stage IV  | 12                          |
| Metastasis           | To liver  | 12                          |
|                      | To other organs | 18                  |
|                      | Unknown/not done | 20              |
| Chemotherapy         | Yes      | 50                          |
|                      | No       | 0                           |
| Surgery after relapse| Yes      | 0                           |
|                      | No       | 50                          |
value of cycle thresholds (Ct) for six genes involved in the algorithm.

### 2.6. CEA Gene Assay and Six-gene Assay for CTC detection

CEA Gene Assay and Six-gene Assay based on mRNA expression of corresponding genes were performed by RT-PCR with samples prepared from spiked cell cultures and PBMC as described previously (Sato et al., 2012). Briefly, the six CRC-associated genes (CEA, EpCAM, CK19, MUC1, EGFR and C-Met) and housekeeping genes B2M and GAPDH were quantified by RT-PCR with optimized primer sets. The Ct value for each gene was the cycle number where the amplification signal reached a threshold of 0.4 over baseline, and Ct of 40 was assigned when this threshold was not reached by the 40th cycle. Together with the Ct value from CEA Gene Assay and Six-gene Assay, algorithms were used to quantify the number of CTC.

### 2.7. CEA Gene Assay and Six-gene Assay for prediction of 2-year PFS

To evaluate and compare the sensitivity and accuracy of CEA Gene Assay and Six-gene Assay in predicting PFS, the 2-year PFS of all 50 CRC patients were collected. With the number of CTC of each CRC patient respectively calculated by CEA Gene Assay and Six-gene Assay, patients were divided into two groups having CTC levels less than or equal to the selected cutoff value, and those having CTC levels greater than the selected cutoff value. Time-dependent covariate Cox regression was used to analyze the relation between the amount of CTC and PFS.

### 2.8. Statistical analysis

Statistical analysis of the obtained data was carried out using the spss software package, release 12.0.1 (IBM, Armonk, NY, USA). Raw data were entered into Excel (Microsoft, Redmond, WA, USA) files and converted automatically into the statistical packages. Spearman’s rank correlation coefficient was introduced to assess the association between CEA Gene Assay and Six-gene Assay. CTC panel performance of CEA Gene Assay and Six-gene Assay in diagnosing CRC was calculated at different CTC number variances and functioned as a surrogate marker for constructing receiver operating characteristic (ROC) curves, where area under the ROC curve (AUC) reflects diagnostic capability. Time-dependent covariate Cox regression was used to analyze the relation between the amount of CTC and PFS. P values were based on the likelihood ratio test, and \( P < 0.05 \) was considered statistically significant.

### 3. Results

#### 3.1. Characteristics of patients

All 50 patients enrolled in this study had a histologically confirmed diagnosis of CRC (Table 1). The patient cohort included 28 male (56%) and 22 female (44%) patients, with an average age of 67 years at diagnosis (range 45–78 years). Thirty-eight patients (76%) were stage III and 12 patients (24%) were stage IV CRC. Thirty patients (60%) had metastases; 12 of these patients (24%) had tumors located in the liver and 18 patients (36%) tumors located in other organs, not liver.

#### 3.2. Establishment of CTC algorithms for CEA Gene Assay and Six-gene Assay

Through cell spiking assay using different but known amounts of SW1116, SW48, HCA-7, LoVo, SW620 and RKO cancer cells, and subsequent RT-PCR, we successfully established the following CTC equations for CEA Gene Assay and Six-gene Assay. Based on previous studies (Marachelian et al., 2017; Vandesompele et al., 2002), a summary \( \Delta \text{Ct} \) for the six tested genes was calculated by subtracting the GM of the Ct for two reference genes from the GM of the Ct for the six genes. With a direct correlation between CTC numbers and \( \Delta \text{Ct} \) (Six-gene) value, this CTC quantitative equation and corresponding transformation table (Table 2) allow us to calculate CTC numbers by the \( \Delta \text{Ct} \) (Six-gene) value of unknown blood samples. For CEA Gene Assay, \( \Delta \text{Ct} \) (CEA) was calculated in a similar way, with only CEA gene included in the equation and transformation table (Table 3). (I) CTC equation for Six-gene Assay:

\[
\Delta \text{Ct}(\text{Six-gene}) = 6 \sqrt{\frac{\text{Ct}(\text{CEA}) \times \text{Ct}(\text{EpCAM}) \times \text{Ct}(\text{CK19}) \times \text{Ct}(\text{MUC1}) \times \text{Ct}(\text{EGFR}) \times \text{Ct}(\text{C-met}) - 2 \sqrt{\text{Ct}(\text{B2M}) \times \text{Ct}(\beta - \text{actin})}}}
\]


(II) CTC equation for CEA Gene Assay:

\[ \Delta C_t(\text{CEA}) = C_t(\text{CEA}) - \sqrt[2]{C_t(\text{B2M})} \times C_t(\beta - \text{actin}) \]

3.3. Superiority of Six-gene Assay over CEA Gene Assay in CTC detection of CRC patients

After establishment of the above CEA Gene Assay and Six-gene Assay algorithms, we applied them to evaluate CTC in 10 healthy donors. Our data demonstrated that these samples were all negative for CTC with both CEA Gene Assay and Six-gene Assay. Next, six CRC cell lines were spiked respectively into blood samples of 10 healthy donors, followed by RT-PCR and subsequent CEA Gene Assay and Six-gene Assay, respectively. Six-gene Assay showed a significantly higher sensitivity than CEA Gene Assay; for instance, Six-gene Assay could detect one CRC cell among \(10^6\) PBMC in all the tested cell lines, but although CEA Gene Assay could detect one CRC cell among \(10^6\) PBMC in HCA-7, LoVo, SW620 and RKO cell lines, it could not detect CRC cells < 100 among \(10^6\) PBMC in SW1116 and SW48 cell lines (Figs 1 and S1). On the other hand, compared with CEA Gene Assay, the observed CRC cell numbers were closer to the spiked numbers in the dilution series (1, 10, 100 and 1000 cells/mL of blood) in Six-gene Assay.

To confirm these in vitro findings, we further determined the superiority of Six-gene Assay to CEA Gene Assay with clinical samples in which patient samples were defined as CTC-positive once one or more cancer cells were detected. Forty-one samples (82%) were CTC-positive with Six-gene Assay (CTC numbers: 5.2–4.4) (Fig. 2). Although there was a significant correlation between Six-gene Assay and CEA Gene Assay (Spearman \(r = 0.89, P < 0.01\)), only 35 samples (70%) were found to be CTC-positive in CEA Gene Assay, six patients being false-negative in this single gene-based CTC test (highlighted as red points in Fig. 2).

3.4. Diagnostic performance of CEA Gene Assay and Six-gene Assay

To evaluate further the value of CEA Gene Assay and Six-gene Assay in diagnosing CRC, ROC curves were constructed to determine the differences between these two assays (Fig. 3). The AUC of ROC curve of CEA Gene Assay was 0.8706, whereas that of Six-gene Assay was 0.9490. According to the ROC curve, a relative level of 5 CTC was defined as the optimal cutoff value in CEA Gene Assay for distinguishing CRC patients from healthy donors. At this cutoff value for CTC detection, the sensitivity and specificity of CEA Gene Assay were 77% and 85%, respectively. However, the relative number of CTC defined as the optimal cutoff value for Six-gene Assay was 4. At this cutoff value, the sensitivity and specificity of Six-gene Assay were 87% and 85%, respectively. These data further indicated the significantly higher sensitivity of Six-gene Assay than CEA Gene Assay.

3.5. Superiority of Six-gene Assay to CEA Gene Assay in predicting 2-year PFS of CRC patients

To determine their roles in predicting prognosis of CRC patients, univariate analysis of CTC and 2-year PFS was performed for both CEA Gene Assay and Six-gene Assay (Fig. 4). CTC detection results were classified with three different cutoff values (CTC = 1, 3 and 5, respectively), where the cutoff value of 5 was

| Table 2. Six-gene Assay transformation table. |
|---------------------------------------------|
| \( \Delta C_t \text{ (Six-gene)} \) | CTC number (\( \text{CTC number} \) (\( / \text{mL} \)) |
| \( \geq 16.0 \) | < 1 |
| 14.8–15.9 | 1 |
| 13.6–14.7 | 2 |
| 12.4–13.5 | 3 |
| 11.2–12.3 | 4 |
| 10.0–11.1 | 5 |
| 8.8–9.9 | 6 |
| 7.6–8.7 | 7 |
| 6.4–7.5 | 8 |
| 5.2–6.3 | 9 |
| 4.0–5.1 | 10 |
| < 4 | > 10 |

| Table 3. CEA Gene Assay transformation table. |
|---------------------------------------------|
| \( \Delta C_t \text{ (CEA)} \) | CTC number (\( \text{CTC number} \) (\( / \text{mL} \)) |
| \( \geq 16.0 \) | < 1 |
| 14.8–15.9 | 1 |
| 13.5–14.7 | 2 |
| 12.2–13.4 | 3 |
| 10.9–12.1 | 4 |
| 9.6–10.8 | 5 |
| 8.3–9.5 | 6 |
| 7.0–8.2 | 7 |
| 5.7–6.9 | 8 |
| 4.4–5.6 | 9 |
| 3.0–4.3 | 10 |
| < 3 | > 10 |
approximately the median of detectable CTC values in Six-gene Assay. As indicated in Fig. 3, the cutoff value of 5 resulted in wider separations between groups (CTC > 5, CTC ≤ 5) compared with those at cutoff values of 1 and 3 in both CEA Gene Assay and Six-gene Assay. Consistent with this observation, the difference of PFS between CTC ≤ 5 and CTC > 5 was statistically significant in both assays (P = 0.04 and 0.004, respectively), whereas those at cutoff values of 1 and 3 were not. These data indicate that both CEA Gene Assay and Six-gene Assay at a CTC cutoff value of 5 possess predictive roles for disease progression and patient survival. One thing we would like to point out here is that at all three cutoff values, Six-gene Assay led to wider separations than CEA Gene Assay, and the statistical P values obtained with Six-gene Assay were 2–10 times lower than those obtained in CEA Gene Assay, both suggesting a higher sensitivity of Six-gene Assay in predicting PFS in CRC patients.

4. Discussion
In clinics, several strategies, such as tumor-specific markers, fine-needle aspiration biopsy and diagnostic imaging systems, are used to evaluate the status of cancers and the anti-cancer therapeutic effects. However, many of these methods are invasive and may even cause tumor metastasis (Miller et al., 2016).
Meanwhile, micrometastasis and small metastatic lesions are usually undetectable by clinical imaging procedures (e.g. CT and MRI scans) (Bardelli and Pantel, 2017). For instance, the major limitation of CT is its low inherent contrast resolution, which is about 1 cm; thus tumors with diameters smaller than this can not be detected easily. More sensitive and less invasive tools are needed to ensure more accurate and timely diagnosis, as well as more effective treatments (Li et al., 2015; Surinova et al., 2015). In the past decade, studies on CTC have attracted great interest, and CTC value is now considered a useful marker for evaluating the tumor status, therapeutic response and prognosis of patients with multiple types of carcinoma including CRC (van Dalum et al., 2015; Hardingham et al., 2015; Lalmahomed et al., 2015). For instance, Cell Search® and the TRC method have been used to measure CTC in blood samples from CRC patients (Gorges et al., 2016; Sato et al., 2012). Although these two methods are reproducible, they are both single gene-based (EpCAM- and CEA-based, respectively). As a result, EpCAM-negative CTC would be missed by Cell Search®, and CEA-negative CTC are not detectable with the TRC method. Therefore, both strategies are not comprehensive enough, due to the complexity and heterogeneity of CTC.

To overcome the limitations of single gene-based CTC detection, for the first time, we herein adopted six CRC-related genes—CEA, EpCAM, CK19, MUC1, EGFR and C-Met—to quantify CTC in CRC patients. We successfully constructed an algorithm for Six-gene Assay using a spiking assay and RT-PCR analysis with six CRC cell lines expressing different levels of the above six genes. CEA is highly expressed in CRC but it has a low expression level in normal tissues. Moreover, monitoring of serum CEA during chemotherapy may provide a predictor for patient survival in CRC (Allen-Mersh et al., 1987). Therefore, CEA Gene Assay was used as a single gene-based control to evaluate this novel Six-gene Assay. The algorithms developed in this study for CEA Gene Assay and Six-gene Assay allowed us to calculate the number of CTC in blood samples through the mRNA quantity of either CEA gene or the six CRC-related genes. This is the first report on the establishment of a multiple gene-based algorithm for CTC detection in CRC.

Furthermore, by using blood samples spiked with six CRC cell lines as well as blood samples from 50 relapsed CRC patients, we demonstrated that CTC detection using Six-gene Assay was more accurate and sensitive than CEA Gene Assay. The Six-gene Assay could detect as little as one cancer cell among $10^6$ PBMC for all six CRC cell lines, whereas the detection threshold for CEA Gene Assay was 100 cancer cells for SW1116 and SW48 cell lines. The cancer cell numbers determined by Six-gene Assay were closer to the spiked numbers than was CEA Gene Assay. The superiority of Six-gene Assay in CTC detection was further confirmed by clinical studies, as blood samples from 50 CRC patients were all positive with Six-gene Assay but six of them were negative in CEA Gene Assay (false-negative rate of 12% in CEA Gene Assay). We
also found that Six-gene Assay CTC panel shows better AUC compared with CEA Gene Assay, indicating better performance of Six-gene Assay than CEA Gene Assay in diagnosing CRC. In terms of predicting prognosis of CRC, our data showed that although the difference in PFS between CTC ≤ 5 and CTC > 5 was statistically significant in both assays, Six-gene Assay led to wider separations and much lower \( P \) values compared with CEA Gene Assay at all three cutoff values (CTC = 1, 3 and 5, respectively). These findings demonstrated that Six-gene Assay is a novel, independent and more effective predictor of PFS in CRC compared with CEA Gene Assay.

In summary, Six-gene Assay as validated in this study holds great promise as a novel and sensitive biomarker for early diagnosis, evaluation of therapeutic responses, as well as prognostic prediction in CRC patients. Compared with single gene assays, e.g. Cell Search®, the TRC method and CEA Gene Assay used in this study, Six-gene Assay could potentially overcome the heterogeneity of CRC samples. Particularly, as the first multiple gene-based algorithm for measuring CTC in CRC, Six-gene Assay may provide a useful strategy or model system for future development of precision CTC detection and CTC-related clinical practices. However, a number of factors, including chemotherapy and other types of treatment previously received by patients, may cause additional heterogeneity of CTC in patients. Therefore, some blood specimens from CRC patients may not have detectable mRNA of either a specific gene or the six genes validated in the present study, even though disease is present by standard evaluations. Integration of Six-gene Assay with other traditional methods is necessary for precision and personalized medical treatment in CRC. Furthermore, the CRC-relevant genes selected for analysis and the possible difference in the weight of...
each gene in the algorithm may need to be further optimized to cover as much CTC as possible and to improve the promising Six-gene Assay; this could be achieved by future clinical studies including larger numbers of CRC patients.

5. Conclusions

This study investigated whether quantifying the expression of six CRC-related genes in the blood could improve disease assessment through detection of CTC and thereby improve progression prediction in relapsed CRC patients. Through cell spiking assay and RT-PCR, we successfully generated a novel algorithm, named Six-gene Assay, based on the mRNA expression of CEA, EpCAM, CK19, MUC1, EGFR and C-Met in six CRC cell lines. Furthermore, using CEA Gene assay as the single-gene assay control, clinical validation of Six-gene Assay with 50 blood samples from relapsed CRC patients demonstrated its superiority in defining disease status and predicting PFS. The Six-gene Assay is the first multiple gene-based algorithm for CTC detection in CRC, and thus provides a useful strategy or valuable model for CTC-related research and clinical practices.

Acknowledgements

The authors thank the healthy volunteers and CRC patients for their participation in this clinical study. This work was supported by the Key Specialty Construction Project of Pudong Health and Family Planning Commission of Shanghai (No: PWZz2013-06), Shanghai Science and Technology Commission Foundation (No: 16ZR1431400), Open Foundation from Key Laboratory of Tumor Molecular Diagnosis and Individualized Medicine of Zhejiang Province (No: ZJZLSYS001), Science Technology Research Program of Zhejiang Province (No. 2017C33047), the National Natural Science Foundation of China (Nos 21574118, 21722405), and Zhejiang Provincial Natural Science Foundation of China (Nos 21574118, 2161002). All authors approved the final version of the manuscript, including the authorship list.

Conflicts of interest

The authors declare no conflict of interest.

References

de Albuquerque A, Kubisch I, Stolzel U, Ernst D, Boese-Landgraf A, Breier G, Stammering G, Fersis N and Kaul S (2012) Prognostic and predictive value of circulating tumor cell analysis in colorectal cancer patients. J Transl Med 10, 222.

Allen-Mersh TG, Kemeny N, Niedzwiecki D, Shurgot B and Daly JM (1987) Significance of a fall in serum CEA concentration in patients treated with cytotoxic chemotherapy for disseminated colorectal cancer. Gut 28, 1625–1629.

Bardelli A and Pantel K (2017) Liquid biopsies, what we do not know (yet). Cancer Cell 31, 172–179.

Cayrefourcq L, Mazard T, Joosse S, Solassol J, Ramos J, Assenat E, Schumacher U, Costes V, Maudelonde T, Pantel K et al. (2015) Establishment and characterization of a cell line from human circulating colon cancer cells. Cancer Res 75, 892–901.

Chaffer CL and Weinberg RA (2011) A perspective on cancer cell metastasis. Science 331, 1559–1564.

Cohen SJ, Alpaugh RK, Gross S, O’Hara SM, Smirnov DA, Terstappen LW, Allard WJ, Bilbee M, Cheng JD, Hoffman JP et al. (2006) Isolation and characterization of circulating tumor cells in patients with metastatic colorectal cancer. Clin Colorectal Cancer 6, 125–132.

van Dalum G, Stam GI, Scholten LF, Mastboom WJ, Vermeulen I, Tibbe AG, De Groot MR and Terstappen LW (2015) Importance of circulating tumor cells in newly diagnosed colorectal cancer. Int J Oncol 46, 1361–1368.

Gasch C, Bauernhofer T, Pichler M, Langer-Freitag S, Reeh M, Seifert AM, Mauermann O, Izbicki JR, Pantel K and Riedtendorf S (2013) Heterogeneity of epidermal growth factor receptor status and mutations of KRAS/PIK3CA in circulating tumor cells of patients with colorectal cancer. Clin Chem 59, 252–260.

Gorges TM, Stein A, Quidde J, Hauch S, Rock K, Riedtendorf S, Joosse SA and Pantel K (2016) Improved detection of circulating tumor cells in metastatic colorectal cancer by the combination of the cell search® System and the AdnaTest®. PLoS One 11, e0155126.

Grasso CS, Giannakis M, Wells DK, Hamada T, Mu XJ, Quist M, Nowak JA, Nishihara R, Qian ZR, Inamura K et al. (2018) Genetic mechanisms of immune evasion in colorectal cancer. Cancer Discov 8, 730–749.
Haber DA and Velculescu VE (2014) Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA. *Cancer Discov* 4, 650–661.

Hardingham JE, Grover P, Winter M, Hewett PJ, Price TJ and Thierry B (2015) Detection and clinical significance of circulating tumor cells in colorectal cancer—20 years of progress. *Mol Med* 21(Suppl 1), S25–S31.

Inuma H, Watanabe T, Mimori K, Adachi M, Hayashi N, Tamura J, Matsuda K, Fukushima R, Okinaga K, Sasaki M et al. (2011) Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes’ stage B and C colorectal cancer. *J Clin Oncol* 29, 1547–1555.

Kim JC, Kim SY, Cho DH, Ha YJ, Choi EY, Kim CW, Roh SA, Kim TW, Ju H and Kim YS (2011) Novel chemosensitive single-nucleotide polymorphism markers to targeted regimens in metastatic colorectal cancer. *Clin Cancer Res* 17, 1200–1209.

Lalmahomed ZS, Mostert B, Onstenk W, Kraan J, Ayez N, Gratamou JW, Grunhagen D, Verhoef C and Sleijfer S (2015) Prognostic value of circulating tumour cells for early recurrence after resection of colorectal liver metastases. *Br J Cancer* 112, 556–561.

Li Y, Zheng Q, Bao C, Li S, Guo W, Zhao J, Chen D, Gu J, He X and Huang S (2015) Circular RNA is enriched and stable in exosomes: a promising biomarker for cancer diagnosis. *Cell Res* 25, 981–984.

Mao C, Wu XY, Yang ZY, Threapleton DE, Yuan JQ, Yu YY and Tang J (2015) Concordant analysis of KRAS, BRAF, PIK3CA mutations, and PTEN expression between primary colorectal cancer and matched metastases. *Sci Rep* 5, 8065.

Marachelian A, Villalbaña JG, Liu CW, Liu B, Goodarzian F, Lai HA, Shimada H, Tran HC, Parra JA, Gallego R et al. (2017) Expression of five neuroblastoma genes in bone marrow or blood of patients with relapsed/refractory neuroblastoma provides a new biomarker for disease and prognosis. *Clin Cancer Res* 23, 5374–5383.

Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, Stein KD, Alteri R, Jemal A (2016) Cancer treatment and survivorship statistics, 2016. *CA Cancer J Clin* 66, 271–289.

Ning Y, Hanna DL, Zhang W, Mendez A, Yang D, El-Khoueiry R, Matsusaka S, Sunakawa Y, Stremitzer S, Parekh A et al. (2015) Cytokeratin-20 and survivin-expressing circulating tumor cells predict survival in metastatic colorectal cancer patients by a combined immunomagnetic qRT-PCR approach. *Mol Cancer Ther* 14, 2401–2408.

Okugawa Y, Grady WM and Goel A (2015) Epigenetic alterations in colorectal cancer: emerging biomarkers. *Gastroenterology* 149, 1204–1225.e1212.

Punt CJ, Koopman M and Vermeulen L (2017) From tumour heterogeneity to advances in precision treatment of colorectal cancer. *Nat Rev Clin Oncol* 14, 235–246.

Sanchez-Lopez E, Flashner-Abramson E, Shalapour S, Zhong Z, Taniguchi K, Levitzki A and Karin M (2016) Targeting colorectal cancer via its microenvironment by inhibiting IGF-1 receptor-insulin receptor substrate and STAT3 signaling. *Oncogene* 35, 2634–2644.

Sato N, Hayashi N, Imamura Y, Tanaka Y, Kinoshita K, Kurashige J, Saito S, Karashima R, Hirashima K, Nagai Y et al. (2012) Usefulness of transcription-reverse transcription concerted reaction method for detecting circulating tumor cells in patients with colorectal cancer. *Ann Surg Oncol* 19, 2060–2065.

Schroeder A, Mueller O, Stocker S, Salowsky R, Leiber M, Gassmann M, Lightfoot S, Menzel W, Granzow M and Ragg T (2006) The RIN: an RNA integrity number for assigning integrity values to RNA measurements. *BMC Mol Biol* 7, 3.

Shimada R, Inuma H, Akahane T, Horiuichi A and Watanabe T (2012) Prognostic significance of CTC and CSCs of tumor drainage vein blood in Dukes’ stage B and C colorectal cancer patients. * Oncol Rep* 27, 947–953.

Siegel RL, Miller KD, Jemal A (2017) Cancer statistics, 2017. *CA Cancer J Clin* 67, 7–30.

Siegel RL, Miller KD, Jemal A (2018) Cancer statistics, 2018. *CA Cancer J Clin* 68, 7–30.

Stadler ZK, Battaglin F, Middha S, Hechtman JF, Tran C, Cercek A, Yaeger R, Segal NH, Varghese AM, Reidy-Lagunes DL et al. (2016) Reliable detection of mismatch repair deficiency in colorectal cancers using mutational load in next-generation sequencing panels. *J Clin Oncol* 34, 2141–2147.

Suirnova S, Choi M, Tao S, Schuffler PJ, Chang CY, Clough T, Vyslouzil K, Khoylou M, Srovnal J, Liu Y et al. (2015) Prediction of colorectal cancer diagnosis based on circulating plasma proteins. *EMBO Mol Med* 7, 1166–1178.

Van Cutsem E, Cervantes A, Nordlinger B, Arnold D, Group, E.G.W. 2014. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 25 (Suppl 3), iii1–iii9.

Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F (2002) Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. * Genome Biol* 3, RESEARCH0034.

Yaeger R, Chatila WK, Lipsyc MD, Hechtman JF, Cercek A, Sanchez-Vega F, Jayakumaran G, Middha S, Zehir A, Donoghue MTA et al. (2018) Clinical sequencing
defines the genomic landscape of metastatic colorectal cancer. Cancer Cell 33, 125–136.e123.
Yanagawa R, Furukawa Y, Tsunoda T, Kitahara O, Kameyama M, Murata K, Ishikawa O and Nakamura Y (2001) Genome-wide screening of genes showing altered expression in liver metastases of human colorectal cancers by cDNA microarray. Neoplasia 3, 395–401.

Supporting information

Additional supporting information may be found online in the Supporting Information section at the end of the article.

Fig. S1. Evaluation of cell detection efficiency of CEA Gene Assay and Six-gene Assay.